Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	32.77B -19.8%
Revenue (ttm)	6.42B +22.8%
Net Income	1.32B +3.3%
EPS	0.66 +3.1%
Shares Out	1.98B
PE Ratio	25.12
Forward PE	19.84
Dividend	0.15 (0.91%)
Ex-Dividend Date	Sep 25, 2025

Volume	15,647,878
Average Volume	10,618,755
Open	16.54
Previous Close	16.57
Day's Range	16.31 - 16.55
52-Week Range	16.06 - 23.61
Beta	0.27
RSI	46.17
Earnings Date	Mar 28, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,298
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2024, SHA:600161's revenue was 6.03 billion, an increase of 16.44% compared to the previous year's 5.18 billion. Earnings were 1.55 billion, an increase of 39.58%.